Price (delayed)
$2.21
Market cap
$562.8M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.14
Enterprise value
$604.4M
Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are
There are no recent dividends present for MRVI.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.